about
Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approachA Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel DiseasesTrefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodiesCT-P13: design, development, and place in therapyCrohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.The Th17/Treg Immune Imbalance in Ulcerative Colitis Disease in a Chinese Han Population.Cytokine Networks and T-Cell Subsets in Inflammatory Bowel DiseasesOptimizing the Use of Biologic Therapies in the Management of Inflammatory Bowel Disease.Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases.Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature.Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune DisordersTherapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Review of pulmonary adverse effects of infliximab therapy in Crohn's disease.Will novel oral formulations change the management of inflammatory bowel disease?Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.Emerging biologics in inflammatory bowel disease.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Demystifying the cytokine network: Mathematical models point the way.The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Schiff base complexes of copper and zinc as potential anti-colitic compounds.A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative ColitisColonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques.The intestinal microbiota determines the colitis-inducing potential of T-bet-deficient Th cells in mice.Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.
P2860
Q26747744-CD8774B0-85CB-40BD-BEB7-E5713D40DDB0Q26775384-94208F3F-3B77-4FA5-83F5-C6071C53464FQ28468381-34E6AC7D-79E4-49A7-A8BC-C79CFB969D58Q33803728-C3CC9CF0-AFEB-4FF3-B718-ADF771CC1AA7Q35933419-276E8BDD-DF6B-450E-B050-A5B820871709Q36605404-BE87A682-BB0B-45EE-A036-541577816DE5Q36818290-CC866C28-D602-458F-9865-08D0AF27A329Q36848459-D98F7112-9275-4792-A803-CDAB83286988Q36996334-534AD97A-E6A7-4D7D-BD11-D6B9AF9BD539Q37098441-4DADB3CA-089F-4B3B-BD6A-FF348A2EA05EQ37421529-EC305D8D-1B0A-4320-B049-3F1180F1AF69Q37492026-C01C7360-E868-4E6C-8031-810487FE7F8EQ38620415-80BBDE68-1B4A-4462-8E30-944390F938ABQ38669163-8D48F0DF-DB79-43D6-9C25-C285FEDD1DE7Q38735477-1CC1D6E7-591D-4F98-BE67-74EE3719D6E9Q38753468-50AF951C-E511-4A45-9228-B989E31602ADQ38769875-D1DD60D6-C4D7-4F78-80E8-8DC1DF6BE76EQ38824505-335F1CA0-4747-49CA-BD9E-4F7DF09DA74DQ38826447-877518BA-0448-495D-9B6B-4EAA1652C671Q38850063-76E2C803-4DD2-488A-A7ED-6BD712420566Q38881849-0EC29E22-CFFC-42D2-8F4F-E2D73215DF54Q38883385-645EBAC2-C8D3-4F3E-82DC-5AE0F75D3DFEQ39004625-77DDE674-FA9F-4500-9940-E56ECF124BB6Q39018436-E1B47FAB-DC92-46EF-8507-498EB3D743ACQ39029793-6FC62519-8835-4941-A521-3BF02A1D0F39Q39169669-72377630-8CA8-424B-8802-E6A8CC05D1E0Q39435409-913FEA65-F8E1-49A2-8C65-5F9287D61E4FQ41122444-3937D82B-A509-48F5-A6EF-C6A264B31C39Q42278522-30EE3787-4B52-4CA9-89C1-8E4A117ED170Q42369594-B782CF82-07C3-47BB-8E4C-310454A4FA2BQ42378152-1308C8F9-3BD4-403E-9EAF-E3D11D71E394Q42651996-C146A66C-CC41-4B2F-98A8-321A1F696970Q46003614-9ABFDD70-7E17-4D4F-AE9C-EEA1CC2F9C7FQ46345854-235A35CA-3DC2-4A9A-BCD2-C968B7BBCBD0Q47095222-3E461D20-39E7-40D4-A76E-00F67082D089Q47095956-4A157E3E-5F39-4031-A6AD-EE6F682034F3Q47381745-DC485A81-84AB-4139-9A7C-6F1462F9050BQ48030014-1C7A9B87-2ACA-47FF-9B6A-A62C29693B7CQ49126220-0E9A5AD1-9AA9-4562-A83F-52554D05FCA7Q49315243-2ACA39EF-B1D0-4C02-95D6-169632CBE719
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Biologic agents for IBD: practical insights.
@en
type
label
Biologic agents for IBD: practical insights.
@en
prefLabel
Biologic agents for IBD: practical insights.
@en
P2860
P1476
Biologic agents for IBD: practical insights.
@en
P2093
Lucine Vuitton
Silvio Danese
P2860
P2888
P304
P356
10.1038/NRGASTRO.2015.135
P407
P577
2015-08-18T00:00:00Z
P6179
1048916938